Pharmaceutical company Lisheng (002393.SZ): Apomiesterin tablets approved for marketing authorization application.

Wisdom Finance and Economics APP news, Lisheng Pharmaceutical (002393.SZ) announced that its subsidiary Tianjin Central Pharmaceutical Co., Ltd. ("Central Pharmaceutical") has received the "Drug Registration Certificate" for 10mg specification of Apmiste Tablets, the "Drug Registration Certificate" for 20mg specification of Apmiste Tablets, and the "Drug Registration Certificate" for 30mg specification of Apmiste Tablets issued by the National Medical Products Administration. The above-mentioned drugs have passed the application for drug market authorization.